Catalent (CTLT) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Catalent, Inc. Reports First Quarter Fiscal Year 2017 Results
November 7, 2016 4:15 PM ESTQ1'17 revenue $442.2 million increased 5% as-reported, or 7% in constant currency from the prior year period. Acquired Pharmatek Laboratories, a West Coast, U.S.-based specialist in drug development and clinical manufacturing; adds extensive formulation and development capabilities. Triphase Accelerator has obtained worldwide rights to an oncology treatment developed using Catalent's proprietary SMARTag technology. Reached an agreement with Moderna Therapeutics to support near-term Good Manufacturing Practice (GMP) efforts for Phase 1/2 clinical studies for its personalized cancer vaccines.... More
